CMB International Securities | Equity Research | Company Update

# New China Life (1336 HK)

## Set off to a challenging 2020

NCI's 2019 results were mixed, reflecting both achievements and uncertainties. Net profit +83.8% YoY, NBV -19.9% and EV +18.4%. 2019 is a year of reflection and preparation for NCI. Setting off again in 2020, the Company will continue to face challenges executing new strategic missions, which aims for balanced growth of volume and quality. Nevertheless, current low valuation offers cushion.

- Result highlights.1) Net profit increased 83.8% YoY to RMB 14.56bn, thanks primarily to increase in investment income and tax deductions; 2) Agent headcount rose 37% YoY/31.3% HoH to 507,000 at YE19. Team expansion laid foundation for premium and business growth. 3) Underwriting quality improved, underpinned by declining surrender rate and increasing 25-month persistency ratio. 4) Total investment yield edged up 0.3ppt to 4.9%, boosting investment assets to grow 20%. Proportion of common stocks and funds reached 12.2% at YE19, up 1.5ppt YoY.
- Result negatives. 1) NBV -19.9% YoY (-8.7%/-32.5% in 1H/2H). Not only FYRP decreased (-6.7%), but also NBV margin shrank 11.6ppt to 36.5% on standardized premium basis. 2) Agent qualified rate declined 5.7ppt to 33.1%, which foreshadows difficulties in 2020 to solidify agent team and boost productivity. 3) Net investment yield inched down 0.2ppt to 4.8%, though total investment yield edged up 0.3ppt to 4.9%. As interest rate goes down and previous high-yield investment matures, the Company's NIY may be under pressure. 4) EV increased 19.8% primary due to positive investment experience variances and other adjustment, instead of more "organic" new business growth.
- Risks. 1) NBV margin pressure; 2) FYRP growth despite above-peers GWP growth in Jan-Feb; 3) Investment yield decline.
- Trim TP to HK\$ 37.30. Reiterate BUY. We revise up CoR assumption to reflect market volatilities and lower NBV/EV forecast to reflect margin pressure. We thereby trim TP to HK\$ 37.3. The Company's H-share is now trading at merely 0.31x FY20E P/EV. Too much concerns have been priced in.

#### Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
GWP (RMB mn)	122,286	138,131	152,231	167,375	183,105
YoY Growth (%)	11.9	13.0	10.2	9.9	9.4
Total income (RMB mn)	151,964	172,103	189,238	206,757	225,798
Net profit (RMB mn)	7,922	14,559	11,728	13,770	15,296
EPS (RMB)	2.54	4.67	3.76	4.41	4.90
EPS CHG (%)	47.2	83.8	-19.4	17.4	11.1
Consensus EPS (RMB)	2.54	4.37	3.83	4.36	5.22
Р/В (х)	1.02	0.79	0.71	0.64	0.57
P/EV (x)	0.39	0.33	0.31	0.28	0.26
Yield (%)	3.58	6.56	5.28	6.21	6.89
RoEV (%)	13.9	19.8	9.0	10.3	9.6

Source: Company data, Bloomberg, CMBIS estimates



### **BUY (Maintain)**

Target Price	HK\$37.30
(Previous TP	HK\$42.59)
Up/Downside	+56.1%
Current Price	HK\$23.90

#### **China Insurance Sector**

Wenjie Ding, PhD (852) 3900 0856 dingwenjie@cmbi.com.hk

#### Hanbo Xu

(852) 3761 8725 xuhanbo@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	117,404
Avg 3 mths t/o (HK\$ mn)	309.67
52w High/Low (HK\$)	45.84/20.45
Total Issued Shares (mn)	1,034 (H)
	2,085 (A)

Source: Bloomberg

#### **Shareholding Structure**

Central Huijin Investment	31.34%
China Baowu Steel Group	12.09%
Source: HKEx	

#### Share Performance

	Absolute	Relative
1-mth	-21.0%	-13.0%
3-mth	-27.1%	-20.7%
6-mth	-23.4%	-20.4%
Source: Bloomberg		

#### 12-mth Price Performance



#### Biodifio Biodifiberg

#### Auditor: Ernst & Young

#### **Related Reports**

- "Lackluster FYRP growth likely weighs on NBV" – 31 Oct 2019
- 2. "Clearer firm strategy in 2H19" 30 Aug 2019
- 3. "Margin pressure and transition uncertainties" – 2 Jul 2019
- "Strong FYRP growth in 1Q19" 29 Apr 2019




### Figure 1: NCI's 2019 results summary

(RMB mn)									vs. CMBIS
P&L	3Q19	4Q19	QoQ	4Q18	YoY	2018A	2019A	YoY	est.
Gross written premiums	33,897	30,259	-10.7%	22,333	35.5%	122,341	138,171	12.9%	4.6%
Net premiums earned	33,160	30,224	-8.9%	22,401	34.9%	120,002	135,443	12.9%	5.0%
Investment income	8,425	10,733	27.4%	6,812	57.6%	31,185	35,842	14.9%	5.1%
Total income	41,906	41,105	-1.9%	29,331	40.1%	151,964	172,103	13.3%	5.0%
Insurance benefits and claims	(31,584)	(30,919)	-2.1%	(21,066)	46.8%	(109,842)	(125,928)	14.6%	8.8%
Underwriting costs	(4,083)	(3,846)	-5.8%	(3,634)	5.8%	(16,711)	(16,872)	1.0%	4.6%
Admin expenses	(2,893)	(4,632)	60.1%	(3,692)	25.5%	(11,968)	(13,037)	8.9%	6.4%
Total expenses	(39,867)	(39,445)	-1.1%	(28,231)	39.7%	(140,755)	(158,342)	12.5%	7.9%
Associates and JVs	42	282	571.4%	268	5.2%	404	502	24.3%	28.1%
Pre-tax profit	2,429	900	-62.9%	265	239.6%	10,510	13,221	25.8%	-20.3%
Income tax	29	656		(45)		(2,587)	1,339		
Less: Minority interests	-	2	n/a	2	0.0%	1	1		
Net profit	2,458	1,556	-36.7%	220	607.3%	7,922	14,559	83.8%	-8.0%
									vs. CMBIS
B/S	3Q19	4Q19	QoQ	4Q18	YoY	2018A	2019A	YoY	est.
Investment assets	784,969	839,447	6.9%	773,231	8.6%	699,826	839,447	20.0%	5.7%
Total assets	822,083	878,970	6.9%	733,929	19.8%	733,929	878,970	19.8%	6.0%
Insurance contracts liabilities	639,198	658,191	3.0%	594,620	10.7%	594,620	658,191	10.7%	3.8%
Total liabilities	742,275	794,509	7.0%	668,333	18.9%	668,333	794,509	18.9%	6.6%
Equity attr. to shareholders	79,798	84,451	5.8%	65,587	28.8%	65,587	84,451	28.8%	1.0%
									vs. CMBIS
Key indicators	3Q19	4Q19	QoQ	4Q18	YoY	2018A	2019A	YoY	est.
FYRP (RMB mn)	4,299	3,344	-22.2%	3,542	-5.6%	20,734	19,341	-6.7%	-7.5%
NBV (RMB mn)	n/a	n/a	n/a	n/a	n/a	12,210	9,779	-19.9%	-15.7%

Source: Company data, CMBIS estimates





Source: Company data, CMBIS estimates





# **Disclosures & Disclaimers**

#### **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

#### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.